- Details
- (Length of Discussion: 21 min) Tom Keane brings new concepts in androgen deprivation therapy (ADT) to light specifically discussing agonists versus antagonists, new androgen receptor-targeted drugs, including immunotherapy biomarkers, and genomic testing. He reviews the current state of the CRPC treatment and ADT options for use in advanced metastatic disease and concludes with a discussion on tre...
|
- Details
- (Length of Discussion: 5 min) Dr. Thomas Keane discusses a group analysis of an online tool to explore evolving practice patterns among patients with renal cell carcinoma (RCC), a topic presented by Dr. Won Kim from UCSF. The complex and rapidly evolving treatment landscape for advanced RCC poses challenges for healthcare providers, particularly those in community settings, to make treatment decis...
|
- Details
- (Length of Discussion: 5 min) Dr. Thomas Keane reviews the IMmotion 151 Trial, a randomized Phase III Study of Atezolizumab Plus Bevacizumab versus Sunitinib in Untreated Metastatic Renal Cell Carcinoma. A topic presented by Robert J. Motzer, MD at the 2018 ASCO GU 2018 meeting. In this oral abstract session, Dr. Motzer presented the first phase III randomized clinical trial combining a PD-L1/PD-1...
|
- Details
- (Length of Discussion: 4 min) Dr. Thomas Keane reviews the Subgroup Analysis of Progression-free Survival and Objective Response Rate in the Alliance AO31203 CABOSUN trial for Advanced Renal Carcinoma presentation by Dr. Daniel George at the ASCO GU 2018 meeting. Cabozantinib, a small molecule designed to target the MET and ALK pathways in addition to VEGFR2 pathway has been shown to be superior t...
|
- Details
- (Length of Discussion: 4 min) Dr. Thomas Keane provides a commentary on the The FALCON Trial , the impact of 18F-fluciclovine PET/CT on clinical management choices for men with biochemically recurrent prostate cancer presented at the recent 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium . Eugene Jueren Teoh, MBBS, MRCP from the University of Oxford presented t...
|
- Details
- (Length of Discussion 17 min) Dr. Thomas Keane reviews recent groundbreaking data presented at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium focusing on the much awaiting results of the SPARTAN trial. Dr. Keane started by highlighting the SPARTAN Trial presentation by Dr. Eric Small. A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-r...
|
- Details
- (Length of Update: 4 min) As we start a new year, Dr. Thomas Keane provides an update on exciting news in the area of non-metastatic castration-resistant prostate cancer with the FDA granting priority review for apalutamide as a treatment for non-metastatic castration-resistant prostate cancer. Currently, there are no FDA-approved treatments for patients with non-metastatic CRPC. Watch Video from...
|
- Details
- Dr. Thomas Keane reviews recent data presented at the SIU-ICUD Joint Consultation on Bladder Cancer 2017 conference focusing on a number of presentation highlights. The main purpose of the meeting was for each of the chapter editors to present work from their groups, specifically providing any significant updates from the 2012 edition. They included the level of evidence and grade of recommendatio...
|
- Details
- (Length of Discussion: 25 min) Dr. Thomas Keane reviews recent data presented at the SUO 2017 conference focusing on highlights from the prostate cancer session. He reviews a number of presentations including Prostate Cancer Anxiety in Men Undergoing Active Surveillance (AS), a talk presented by Karim Marzouk, MD, FRCSC. In this analysis, the authors use prospective data from a large institutional...
|
- Details
- Dr. Thomas Keane reviews recent data presented at the SIU 2017 conference focusing on urothelial carcinoma. Highlighting a number of presentations, he focuses on Translational Observations from Mutation Profiling of Muscle Invasive Bladder Cancer a presentation by Seth Lerner and details his summary slide with 5 subtypes and proposed paradigm for management. He also discusses another presentation...
|
